GlaxoSmithKline is recalling prescription-only versions of its heartburn medicine Zantac globally after the U.S. Food and Drug Administration found “unacceptable” levels of a potential carcinogen in ...
GSK’s ViiV Healthcare and its bimonthly pre-exposure prophylaxis (PrEP) medicine Apretude had to make room for another long-acting PrEP option this summer, when rival Gilead Sciences rolled out Yez | ...
GSK committed $270 million up front in recent months to gain access to early-stage assets in the class of cancer therapies known as antibody drug conjugates, or ADCs. The deals are part of a broad ...
Shares of Pfizer rose more than 6%, and the news lifted Eli Lilly, Merck, Amgen, AbbVie and GSK shares as well on investor relief that they would escape the worst of tariffs. U.S. patients currently ...
The GlaxoSmithKline drug, which can be taken orally or intravenously, is made by more than half a dozen companies. leucovorin ...
Swiss drugmaker Novartis' <a href=" target="_blank">(NOVN.S) generics division is buying a GlaxoSmithKline <a href=" target="_blank">(GSK.L) antibiotics business that includes the brands Zinnat, ...
By Alun John, Danilo Masoni, Dimitri Rhodes and Maggie Fick LONDON (Reuters) -European healthcare stocks jumped on Wednesday, mirroring moves in the United States, propelled by a deal between Pfizer ...
"We expect EU pharma to follow suit and negotiate with the Trump administration for exemptions," said Lucy Coutts, investment director at wealth managers JM Finn, which holds shares in GSK ... pay far ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback